Evan Loh climbs the lad­der to be­come CEO at Paratek Phar­ma­ceu­ti­cals; Co­di­ak's Doug Williams takes chair­man's role at AC Im­mune

De­ter­mined to be the good sto­ry that the an­tibi­otics field so des­per­ate­ly needs, Paratek Phar­ma­ceu­ti­cals $PRTK is reshuf­fling its top-lev­el man­age­ment to han­dle a grow­ing com­mer­cial op­er­a­tion. Evan Loh has be­come CEO af­ter climb­ing the lad­der over the past sev­en years (from CMO to pres­i­dent and COO) while Michael Bigham claims the new­ly cre­at­ed po­si­tion of ex­ec­u­tive chair­man. They will over­see life cy­cle ex­pan­sion ini­tia­tives for Nuzyra with chief com­mer­cial of­fi­cer Adam Woodrow, who’s been pro­mot­ed to pres­i­dent. Mean­while, Randy Bren­ner will take up ad­di­tion­al re­spon­si­bil­i­ties in med­ical af­fairs af­ter lead­ing the reg­u­la­to­ry ef­forts for Paratek.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.